|
GSK to seek approval of Theravance lung drug
San Francisco Business Times (blog) GlaxoSmithKline will seek approval of the COPD drug Relovair in the United States and Europe in mid-year, and it and partner Theravance Inc. will continue to talk to regulators about also using the drug for asthma patients. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Glaxo set to submit Relovair to regulatory authorities GSK aims to file new lung drug Relovair in mid-2012 |
View full post on asthma – Google News